Human Movement Science, Maastricht University
Maastricht, 6200MD, Netherlands
NCT Number: NCT02394249
Background of the study:
A sedentary lifestyle and obesity are well known risk factors of type 2 diabetes. The major focus of current guidelines for type 2 diabetes prevention is on energy balance. Physical activity guidelines recommend at least 30 minutes/day of moderate to vigorous physical activity (MVPA). However, no advice is given how the other 23.5 hours of the day should be spent. Several recent epidemiologic studies suggest that excessive sitting, independent of moderate to vigorous physical activity, has detrimental health effects. Another possibility to sit less is by increasing low intensity physical activities as slowly walking and standing. A recent published study of Duvivier and colleagues suggests that sitting less and replacing it by slowly walking and standing has a better effect on insulin action and cardiovascular risk factors than the combination of one hour MVPA per day and sitting the rest of the day in healthy subjects (Duvivier et al. PLOS ONE 2013). Until now this research is not performed in subjects with overweight/obesity.
Objective of the study:
To assess the effect of low intensity physical activity on plasma insulin levels, cognition and mood in subjects with overweight/obesity
Study population:
21 subjects between 40-80 years old with overweight/obesity
Intervention:
2 activity regimes of 4 days: a sitting regime and a "sit less" regime
Looking for future studies?
Notify Me40 year–80 year
All sexes
Interventional
Not applicable
Maastricht, 6200MD, Netherlands
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Information already included in arm descriptions
Time frame: one day after each regime
To assess the effect of low intensity physical activity (LIPA) on plasma insulin levels (as measured as area under the curve during an oral glucose tolerance test)
Time frame: one day after each regime
To assess the effect of LIPA on insulin sensitivity
Time frame: one day after each regime
To assess the effect of LIPA on plasma C-peptide
Time frame: one day after each regime
To assess the effect of LIPA on plasma glucose levels
Time frame: one day after each regime
To assess the effect of LIPA on plasma triglycerides
Time frame: one day after each regime
To assess the effect of LIPA on plasma total cholesterol
Time frame: one day after each regime
To assess the effect of LIPA on plasma non-HDL cholesterol
Time frame: one day after each regime
To assess the effect of LIPA on plasma HDL cholesterol
Time frame: one day after each regime
To assess the effect of LIPA on plasma LDL cholesterol
Time frame: one day after each regime
To assess the effect of LIPA on plasma free fatty acids
Time frame: one day after each regime
To assess the effect of LIPA on plasma apolipoprotein B
Time frame: one day after each regime
To assess the effect of LIPA on plasma apolipoprotein A
Time frame: 2 days: last day of each regime and one day after each regime
To assess the effect of LIPA on mood
Time frame: one day after each regime before and after the oral glucose tolerance test
To assess the effect of LIPA on attention
Time frame: one day after each regime before and after the oral glucose tolerance test
To assess the effect of LIPA on executive function
Time frame: one day after each regime before and after the oral glucose tolerance test
To assess the effect of LIPA on memory
Time frame: last day of each regime
To assess the effect of LIPA on quality of life
Time frame: last day of each regime
To assess the effect of LIPA on sleep
Time frame: one day after each regime
To assess the effect of LIPA on plasma C-reactive protein
Time frame: one day after each regime
To assess the effect of LIPA on plasma interleukin 1
Time frame: one day after each regime
To assess the effect of LIPA on plasma interleukin 6
Time frame: one day after each regime
To assess the effect of LIPA on plasma TNF-alpha
Time frame: one day after each regime
To assess the effect of LIPA on plasma interferon gamma
Time frame: one day after each regime
To assess the effect of LIPA on plasma ICAM-1
Time frame: one day after each regime
To assess the effect of LIPA on plasma VCAM
Time frame: one day after each regime
To assess the effect of LIPA on plasma SAA
Time frame: one day after each regime
To assess the effect of LIPA on plasma E-selectine
Time frame: one day after each regime
To assess the effect of LIPA on plasma vWF
Time frame: one day after each regime
To assess the effect of LIPA on plasma PAI-1
Time frame: one day after each regime
Time frame: one day after each regime
Time frame: one day after each regime
Maastricht University Medical Center
Other
Acronym: SIT LESS 3
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00445627
Body Weight, Diabetes Mellitus
Bethesda, Maryland, United States
View Trial DetailsNCT00340132
Body Weight, Body Weight Changes
Phoenix, Arizona, United States
View Trial DetailsNCT07701005
Body Weight, Digestive System Diseases
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT05384431
Behavior, Body Weight
Waterloo, Ontario, Canada
View Trial Details